Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.

Pischon T, Möhlig M, Hoffmann K, Spranger J, Weikert C, Willich SN, Pfeiffer AF, Boeing H.

Eur J Epidemiol. 2007;22(7):429-38. Epub 2007 Jun 8.


Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

J Am Coll Cardiol. 2013 Aug 20;62(8):717-29. doi: 10.1016/j.jacc.2013.02.098.


Lipid and lipoprotein measurements and the risk of ischemic vascular events: Framingham Study.

Pikula A, Beiser AS, Wang J, Himali JJ, Kelly-Hayes M, Kase CS, Yang Q, Seshadri S, Wolf PA.

Neurology. 2015 Feb 3;84(5):472-9. doi: 10.1212/WNL.0000000000001202. Epub 2015 Jan 7.


Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E.

Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1.


Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.

Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C; German Diabetes and Dialysis Study Investigators.

Am J Kidney Dis. 2009 Nov;54(5):902-11. doi: 10.1053/j.ajkd.2009.06.029. Epub 2009 Sep 25.


The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.

Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, Millan IY, Crowson CS, Curtis JR.

Ann Rheum Dis. 2014 Jul;73(7):1301-8. doi: 10.1136/annrheumdis-2013-204715. Epub 2014 May 5.


Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.

Bangalore S, Fayyad R, Messerli FH, Laskey R, DeMicco DA, Kastelein JJ, Waters DD.

Am J Cardiol. 2017 Feb 1;119(3):379-387. doi: 10.1016/j.amjcard.2016.10.037. Epub 2016 Nov 4.


Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.

Navarro-Millán I, Yang S, DuVall SL, Chen L, Baddley J, Cannon GW, Delzell ES, Zhang J, Safford MM, Patkar NM, Mikuls TR, Singh JA, Curtis JR.

Ann Rheum Dis. 2016 Feb;75(2):341-7. doi: 10.1136/annrheumdis-2013-204987. Epub 2015 Jan 21.


Plasma levels of the proinflammatory chitin-binding glycoprotein YKL-40, variation in the chitinase 3-like 1 gene (CHI3L1), and incident cardiovascular events.

Ridker PM, Chasman DI, Rose L, Loscalzo J, Elias JA.

J Am Heart Assoc. 2014 Jun 23;3(3):e000897. doi: 10.1161/JAHA.114.000897.


Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men.

Cremer P, Nagel D, Mann H, Labrot B, Müller-Berninger R, Elster H, Seidel D.

Atherosclerosis. 1997 Mar 21;129(2):221-30.


Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction.

Sigdel M, Yadav BK, Gyawali P, Regmi P, Baral S, Regmi SR, Jha B.

BMC Res Notes. 2012 Nov 17;5:640. doi: 10.1186/1756-0500-5-640.


Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW.

Circulation. 2005 Jul 5;112(1):110-6. Epub 2005 Jun 27.


Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR.

N Engl J Med. 2002 Nov 14;347(20):1557-65.


C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.

Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA.

Arch Surg. 2007 Nov;142(11):1066-71.


Beyond cholesterol: a new clue to heart disease.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2003 Mar;15(1):4-5. No abstract available.


C-reactive protein levels and outcomes after statin therapy.

Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators.

N Engl J Med. 2005 Jan 6;352(1):20-8.


High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.

Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL.

Stroke. 2009 Oct;40(10):3233-7. doi: 10.1161/STROKEAHA.109.552802. Epub 2009 Jul 30.


Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators.

J Am Coll Cardiol. 2008 Feb 19;51(7):724-30. doi: 10.1016/j.jacc.2007.10.038.

Supplemental Content

Support Center